Summary of COVID-19 hesperidin studies

1. Dupuis et al., Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study

211 patient hesperidin early treatment RCT: 209% higher progression (p=0.36) and 31% improved recovery (p=0.23).
RCT 216 COVID-19 outpatients showing no significant difference in primary outcome (presence of fever, cough, shortness of breath, or anosmia) with hesperidin treatment versus placebo after 14 days, though a post-hoc sensitivity analysis showed significant benefit. Authors suggest that earlier treatment and higher dosage may show greater benefit in future studies.
Nov 2022, Evidence-Based Complementary and Alternative Medicine, https://www.hindawi.com/journals/ecam/2022/3125662/, https://c19p.org/dupuis